Gelesis Holdings, Inc.

GLSH.Q

US36850R2040

Pharmaceuticals

End-of-day quote OTC Markets Other stock markets 06:00:00 2024-04-28 pm EDT			5-day change	1st Jan Change
0.000001 ^USD	-99.99%		-99.95%	-99.93%

Apr. 19	Bidding Procedure Approved for Gelesis Holdings, Inc.	CI
Apr. 09	Motion for Asset Sale Filed by Gelesis Holdings, Inc.	CI

Gelesis Holdings, Inc. Revises Financial Guidance for the Full Year 2022

August 15, 2022 at 07:00 am EDT

Gelesis Holdings, Inc. revised financial guidance for the full year 2022. The company estimates product revenue, net, to be in the range of $27.0 million to $30.0 million, compared to an estimate of $58.0 million previously.

Latest news about Gelesis Holdings, Inc.

Bidding Procedure Approved for Gelesis Holdings, Inc.	Apr. 19	CI
Motion for Asset Sale Filed by Gelesis Holdings, Inc.	Apr. 09	CI
Motion for Joint Administration Approved for Gelesis Holdings, Inc.	Feb. 01	CI
Motion for Joint Administration Filed by Gelesis Holdings, Inc.	Jan. 30	CI
Gelesis Holdings Provides Information to Shareholders	23-10-31	CI
Gelesis Holdings, Inc. Filed for Bankruptcy	23-10-30	CI
PureTech Health plc cancelled the acquisition of the remaining 76.7% stake in Gelesis Holdings, Inc. from Pacific Investment Management Company LLC, Hpso Spv Limited, SSD2 LLC, Cms Medical Venture Investment (HK) Limited and others.	23-10-11	CI
Gelesis Holdings, Inc. Appoints Mr. Yishai Zohar as Interim Principal Financial Officer	23-08-21	CI
Gelesis Holdings, Inc. Appoints Mr. Yishai Zohar as Chief Compliance Officer, Corporate Secretary, Treasurer, Principal Accounting Officer	23-08-21	CI
Gelesis Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Orgenesis Names Elliot Maltz Chief Financial Officer	23-07-13	MT
Elliot Maltz, the Chief Financial Officer of Gelesis Holdings, Inc. Resigns, Effective August 15, 2023	23-07-12	CI
Elliot Maltz, Treasurer, Chief Compliance Officer and Corporate Secretary (And Principal Financial and Accounting Officer) of Gelesis Holdings, Inc. Resigns from All Positions, Effective August 15, 2023	23-07-12	CI
Gelesis Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Gelesis Holdings, Inc. announced that it has received $2 million in funding from PureTech Health LLC	23-04-30	CI
Gelesis Holdings, Inc. Announces Board Changes	23-04-21	CI
Gelesis Holdings, Inc. Announces Resignation of Dominic Perks as Class I Director	23-04-17	CI
Gelesis Holdings, Inc.(OTCPK:GLSH) dropped from S&P TMI Index	23-04-14	CI
Gelesis Holdings, Inc.(OTCPK:GLSH) dropped from Russell 2500 Value-Dynamic Index	23-04-11	CI
Gelesis Holdings, Inc.(OTCPK:GLSH) dropped from Russell 2500 Growth-Dynamic Index	23-04-11	CI
Gelesis Holdings, Inc.(OTCPK:GLSH) dropped from Russell 2000 Value-Dynamic Index	23-04-11	CI
Gelesis Holdings, Inc.(OTCPK:GLSH) dropped from Russell 2000 Growth-Dynamic Index	23-04-11	CI
Gelesis Holdings, Inc.(OTCPK:GLSH) dropped from Russell 2500 Dynamic Index	23-04-11	CI
Gelesis Holdings, Inc.(OTCPK:GLSH) dropped from Russell 2000 Dynamic Index	23-04-11	CI
Gelesis Holdings, Inc.(OTCPK:GLSH) dropped from Russell Microcap Growth Index	23-04-11	CI

Chart Gelesis Holdings, Inc.

Duration

Period

More charts

Company Profile

Gelesis Holdings, Inc. is a commercial stage biotherapeutics company built for consumer engagement. The Company focuses on advancing superabsorbent hydrogel therapeutics for chronic gastrointestinal (GI) diseases including excess weight, type two diabetes, Nonalcoholic Fatty Liver Disease (NAFLD)/ Nonalcoholic Steatohepatitis (NASH), functional constipation (FC), and inflammatory bowel disease. Its product, Plenity, is an orally administered capsule. Plenity is available by prescription via a telehealth consultation with a physician trained in weight management support, with free, unlimited follow-up visits as needed. Consumers can visit myplenity.com for online consultations. Its other pipeline candidate includes GS200 for weight loss in prediabetes and type two diabetes. It is also developing GS300 for the treatment of NAFLD and NASH, and GS500 for the treatment of Functional Constipation (FC).

Sector

Pharmaceuticals

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
GELESIS HOLDINGS, INC.	-99.93%	73
ELI LILLY AND COMPANY	+33.43%	700B
NOVO NORDISK A/S	+27.66%	569B
JOHNSON & JOHNSON	-5.12%	358B
MERCK & CO., INC.	+19.59%	330B
ABBVIE INC.	+4.89%	287B
ASTRAZENECA PLC	+16.13%	236B
NOVARTIS AG	+6.74%	202B
ROCHE HOLDING AG	-9.41%	197B
AMGEN INC.	+4.26%	161B

Other Pharmaceuticals